| pubmed-article:21452285 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C1327616 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C0337076 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C1654934 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:21452285 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:21452285 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21452285 | pubmed:dateCreated | 2011-5-27 | lld:pubmed |
| pubmed-article:21452285 | pubmed:abstractText | T cell activation and the resultant production of interleukin (IL-2) is a central response of the adaptive immune system to pathogens, such as hepatitis C virus (HCV). HCV uses several mechanisms to evade both the innate and adaptive arms of the immune response. Here we demonstrate that liver biopsy specimens from individuals infected with HCV had significantly lower levels of IL-2 compared with those with other inflammatory liver diseases. Cell culture-grown HCV particles inhibited the production of IL-2 by normal peripheral blood mononuclear cells, as did serum from HCV-infected patients. This process was mediated by the interaction of HCV envelope protein E2 with tetraspanin CD81 coreceptor. HCV E2 attenuated IL-2 production at the level of secretion and not transcription by targeting the translocation of protein kinase C beta (PKC?), which is essential for IL-2 secretion, to lipid raft microdomains. The lipid raft disruptor methyl-?-cyclodextrin reversed HCV E2-mediated inhibition of IL-2 secretion, but not in the presence of a PKC?-selective inhibitor. HCV E2 further inhibited the secretion of other cytokines, including interferon-?. CONCLUSION: These data suggest that HCV E2-mediated disruption of the association of PKC? with the cellular secretory machinery represents a novel mechanism for HCV to evade the human immune response and to establish persistent infection. | lld:pubmed |
| pubmed-article:21452285 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21452285 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21452285 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21452285 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21452285 | pubmed:issn | 1527-3350 | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:McKeatingJane... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:Golden-MasonL... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:O'FarrellyCli... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:KelleherDermo... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:VolkovYuriY | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:MitchellSiobh... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:DohertyDerekD | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:DempseyEugene... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:LongAideenA | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:FreeleyMichae... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:StamatakiZani... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:ConroyJennife... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:PrichardDavid... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:PetrovicDanij... | lld:pubmed |
| pubmed-article:21452285 | pubmed:author | pubmed-author:KeoghCatherin... | lld:pubmed |
| pubmed-article:21452285 | pubmed:copyrightInfo | Copyright © 2011 American Association for the Study of Liver Diseases. | lld:pubmed |
| pubmed-article:21452285 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21452285 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:21452285 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21452285 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21452285 | pubmed:pagination | 1846-53 | lld:pubmed |
| pubmed-article:21452285 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:meshHeading | pubmed-meshheading:21452285... | lld:pubmed |
| pubmed-article:21452285 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21452285 | pubmed:articleTitle | Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. | lld:pubmed |
| pubmed-article:21452285 | pubmed:affiliation | Department of Clinical Medicine and Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland. | lld:pubmed |
| pubmed-article:21452285 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21452285 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
